ENOV News and Press, Enovis Corporation From 12/01/22

Wilmington, DE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced that the U.S. Food and Drug Administration (FDA) has approved the STAR Patient Specific Instrumentation (STAR PSI System) for use with the Company...

Wilmington, DE, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, announces the introduction of the DynaNail Helix™, the latest addition to the DynaNail® family and Enovis’ expansive suite of foot and ankle...

Wilmington, DE, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Today, Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced that the company’s ARVIS ® Augmented Reality Surgical Guidance System received the Industry Innovation Award at the this y...

Enovis Corporation (ENOV) Q3 2022 Earnings Conference Call November 02, 2022, 08:00 AM ET Company Participants Derek Leckow - Vice President, Investor Relations Matt Trerotola - Chief Executive Officer Chris Hix - Executive Vice President & Chief Financial Of...

The following slide deck was published by Enovis Corporation in conjunction with their 2022 Q3 earnings call. For further details see: Enovis Corporation 2022 Q3 - Results - Earnings Call Presentation

Enovis Corporation press release ( NYSE: ENOV ): Q3 Non-GAAP EPS of $0.59 beats by $0.11 . Revenue of $383.81M (+6.6% Y/Y) beats by $1.78M , including 7% organic growth over the prior year quarter, with double-digit growth performance across its Reconstructive segm...

Grew sales to $384 million , including 7% organic growth over the prior year quarter, with double-digit growth performance across its Reconstructive segment Reported a net loss of $(1.22) per diluted share from continuing operations and increased it...

Enovis ( NYSE: ENOV ) is scheduled to announce Q3 earnings results on Wednesday, Nov. 2, before market open. The consensus EPS estimate is $0.48 (-11.1% Y/Y) and the consensus revenue estimate is $382.03M (-60.4% Y/Y). Over the last 2 years, ENOV has beaten EPS estim...

Wilmington, DE, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will participate in two investor conferences in November. On Tuesday, November 8, Chris Hix, CFO, and Ben Ber...

Wilmington, DE, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2022 financial results on Wednesday...